Waters Corporation · NYSE:WAT

Waters — Q3 2026 Earnings Presentation

30 slides from Waters's earnings presentation, Nov 3, 2026

  1. Slide 1: Q3 2026 Earnings Call Presentation

    Q3 2026 Earnings Call Presentation November 3, 2026 0

  2. Slide 2: Introduction

    Introduction Caspar Tudor Head of Investor Relations 1

  3. Slide 3: Forward Looking Statements & Non-GAAP Financial Measures

    Forward Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be

  4. Slide 4: Agenda

    Agenda 01 CEO Remarks 02 Financial Results & Outlook 03 Q&A 3

  5. Slide 5: CEO Remarks

    CEO Remarks Dr. Udit Batra President & Chief Executive Officer 4

  6. Slide 6: Key Messages

    Key Messages $43M Guide Double-Digit Raise as Strong Setup Organic CC Momentum Ahead Growth Accelerates Note: CC = Constant Currency. Organic growth presented in constant currency is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAA

  7. Slide 7: Q3 2026 Results – Overview

    Q3 2026 Results – Overview Total Revenue Organic Revenue Biosciences & Diagnostic Solutions Revenue $1.767B $871M $896M Adj. EPS = As Reported: + As Reported: $4.10 +9% +1% Growth Constant Currency: Consistent with +21% +10% Guided Seasonality Note: Growth measures presented in constant currency and

  8. Slide 8: Q3 2026 Results – By Division

    Q3 2026 Results – By Division Analytical Sciences Biosciences Advanced Diagnostics Materials Sciences Q3 2026 Revenue Q3 2026 Revenue Q3 2026 Revenue Q3 2026 Revenue $703M $396M $575M $93M = +8% +2% +2% +7% + + As Reported As Reported As Reported As Reported $500M $75M DS CBU +9% 0% As Reported +17%

  9. Slide 9: Key Growth Acceleration in 3Q Results

    Key Growth Acceleration in 3Q Results Flow Reagent Chemistry LC-MS Consumables Consumables Instruments +HSD +12% +10% IN BIOSCIENCES IN ANALYTICAL IN ANALYTICAL DIVISION SCIENCES DIVISION SCIENCES DIVISION (As Reported Growth) (Constant Currency Growth) (Constant Currency Growth) +400bps +200bps +20

  10. Slide 10: Rapid Execution Initiatives to Accelerate BS/Dx Growth

    Execution Uplift Already Driving MSD BS/Dx Growth Rapid Execution Pricing Action: Central pricing team & deal desks established Result: Net price realization scaled to 120bps in 3Q Initiatives to 150bps+ BS/Dx price realization expected ahead Accelerate Reagent Rental Compliance Action: Dedicated te

  11. Slide 11: Full Tranche of Revenue Synergies Now Entering

    Full Tranche of Revenue Synergies Now Entering Cross Instrument Service Digital Selling Replacement Attachment Commerce Early wins in DMPK Both BACTEC FXI & Now Driving Service Now Leveraging New Cross-Selling FACSDiscover A7 Now Plan Attachment Digital Channels Launched Increase On Track to Deliver

  12. Slide 12: Legacy Waters Remains a Durable HSD Grower

    Legacy Waters Remains a Durable HSD Grower Consistently Still only in Mid-Innings Plus New Growth Delivering Industry- of Instrument Vectors Building Leading Results Replacement Cycle 8% + Reshoring Average Organic + Semiconductor & CC Growth over Idiosyncratic growth drivers still scaling + Data Ce

  13. Slide 13: AI has become a Key Topic with our Customers

    AI has become a Key Topic with our Customers Waters = Key Leader in AI Transformation of the Lab Enabled by a long-standing strategy that leverages a unique market position: 1 2 3 Advancing lab-in-the-loop Leveraging decades of Enabling AI, ML & automation research, while enabling compliant propriet

  14. Slide 14: AI is Reshaping Pharma Research, Development & QC

    AI is Reshaping Pharma Research, Development & QC AI-Driven Volume Increase for Waters AI-Enabled Value Increase for Waters More LC-MS AI generates Each becomes a Launching new Premium SaaS More revenue runs & column more hypotheses physical sample Empower AI features subscription tier per lab consu

  15. Slide 15: MOBILion Acquisition: Enabling End-to-End Proteomics

    MOBILion Acquisition: Enabling End-to-End Proteomics Pairing unique separation technology w/ industry-leading mass spec capabilities Research Development LC-MS Diagnostics Enables Waters to Enter Leveraging Waters Ability Future Menu Expansion Attractive Proteomics to Take Proteomics for Blood-Based

  16. Slide 16: New Sources of Growth Strengthen 2027 Setup

    New Sources of Growth Strengthen 2027 Setup Legacy WAT 2027 Starting 2027 Potential 2027 Potential: Drivers Legacy BD Assumption + Execution Initiatives Organic 7% + Revenue Synergies Revenue MSD+ + Reshoring 5% + AI-Driven Demand Growth MSD 9% + Semiconductor Testing HSD 2H26 Guidance Adj. + Volume

  17. Slide 17: Financial Results & Outlook

    Financial Results & Outlook Amol Chaubal Senior Vice President & Chief Financial Officer 16

  18. Slide 18: Q3 2026 Financial Results

    Q3 2026 Financial Results Total Revenue $1.767B Asia $495M Americas = $749M Europe $523M Organic Revenue $871M + Biosciences & Diagnostic Solutions Revenue $896M Adj. Operating Margin Adj. EPS Adj. EPS Growth 30.1% $4.10 +21% Note: Adj. Operating Margin, Adj. EPS and Adj. EPS growth are non-GAAP fin

  19. Slide 19: Analytical Sciences Division (ASD)

    Analytical Sciences Division (ASD) Category-defining Brands Analytical Sciences Performance Commentary Chemistry Service Q3 2026 Revenue in CC $157M $265M $703M +12% +8%  DD Pharma growth, driven by instrument replacement, GLP-1s, Y/Y Growth India generics, and large molecule in CC applications. +8

  20. Slide 20: Biosciences Division (WBD)

    Biosciences Division (WBD) Category-defining Brands FACSDiscover FACSLyric Horizon Biosciences Performance Commentary Flow Clinical Q3 2026 Revenue $182M $396M +4%  Reagents grew high single- digits, with high-single-digit growth across both research and clinical applications.  Solid demand for ne

  21. Slide 21: Advanced Diagnostics Division (ADx)

    Advanced Diagnostics Division (ADx) Category-defining Brands BACTEC Phoenix Kiestra Synapsys BD MAX Advanced Diagnostics Performance Commentary MSDx MDx & PoC Q3 2026 Revenue $75M $154M $575M +17% (6%)  In Microbiology, ex-China growth was 6%, led by high single-digit = growth in the Americas.  In

  22. Slide 22: Materials Sciences Division (MSD)

    Materials Sciences Division (MSD) Category-defining Brands Materials Sciences Performance Commentary Service Q3 2026 Revenue $29M in CC $93M +9%  Growth led by electronics testing for semiconductor and data center Y/Y Growth applications in CC  Continued strength in thermal +7% analysis for aerosp

  23. Slide 23: FY & Q4 2026 Guidance

    FY & Q4 2026 Guidance FY 2026 Q4 2026 Organic CC Revenue Growth +9.1% to +9.7% Organic CC Revenue Growth +7.0% to +9.0% FX (0.7%) FX (1.5%) Organic Reported Revenue $3.429B to $3.447B Organic Reported Revenue $984M to $1.002B Acquired Business Contribution +$3.050B Acquired Business Contribution +$8

  24. Slide 24: Q&A Session

    Accelerating Q&A Session the Benefits of Pioneering Q3 2026 Earnings Call Science 23

  25. Slide 25: Appendix: GAAP to Non-GAAP Reconciliations

    Appendix GAAP to Non-GAAP Reconciliations 24

  26. Slide 26: Q3 2026 – Reconciliation of Revenue Growth

    Q3 2026 – Reconciliation of Revenue Growth (in millions USD) 2026 2025 Total Reported Revenue (GAAP) 1,767 800 Acquired Business Contribution 896 - Reconciliation of Total Organic Reported Revenue 871 800 Organic Revenue Growth Organic Reported Revenue Growth 9% Currency Translation Impact (1%) Orga

  27. Slide 27: Q3 2026 – Reconciliation of Organic Revenue Growth

    Q3 2026 – Reconciliation of Organic Revenue Growth % Growth % Growth Constant (in millions USD) 2026 2025 Impact of Currency Reported Currency Instruments 282 257 9% (1%) 10% Analytical Sciences Service 265 249 6% (2%) 8% Division (ASD) Chemistry 157 143 10% (2%) 12% Analytical Sciences Division Rev

  28. Slide 28: Q3 2026 – Reconciliation Prior Year Comparable Revenue Growth

    Q3 2026 – Reconciliation Prior Year Comparable Revenue Growth % Growth (in millions USD) 2026 2025 Reported Flow Research 214 212 1% Reconciliation of Biosciences Prior Year Flow Clinical 182 174 4% Comparable Revenue Total Biosciences – Q3 396 387 2% % Growth (in millions USD) 2026 2025 Reported Di

  29. Slide 29: Q3 2026 – Reconciliation of Adjusted Operating Income

    Q3 2026 – Reconciliation of Adjusted Operating Income Q3 2026 Q3 2026 Q3 2026 Q3 2026 (in millions USD) Operating Operating Gross Margin Gross Margin % Income Income % GAAP 887 50.2% 128 7.2% Adjustments: Purchased intangibles and acquisition step-up amortization (a) 80 4.5% 323 18.3% Restructuring

  30. Slide 30: Reconciliation of Adjusted EPS & 2026 Guidance

    Reconciliation of Adjusted EPS & 2026 Guidance Reconciliation of Adjusted Earnings Per Share FY 2026 and Q4 2026 Revenue & EPS Guidance Q3 2026 Q3 2025 Projected Revenue FY 2026 Q4 2026 GAAP $0.82 $2.50 Reported revenue $6,479 - $6,497 $1,801 - $1,819 Adjustments: Acquired business contribution $3,0

Waters — Q3 2026 Earnings Presentation on 6ix